Total Payments
$16,242
2024 Payments
$273.64
Companies
52
Transactions
146
Medicare Patients
28
Medicare Billing
$6,341
Payment Breakdown by Category
Consulting$12,850 (79.1%)
Food & Beverage$3,113 (19.2%)
Education$164.99 (1.0%)
Travel$113.36 (0.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $12,850 | 4 | 79.1% |
| Food and Beverage | $3,113 | 139 | 19.2% |
| Education | $164.99 | 2 | 1.0% |
| Travel and Lodging | $113.36 | 1 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $13,199 | 15 | $0 (2022) |
| Janssen Biotech, Inc. | $208.98 | 6 | $0 (2024) |
| GlaxoSmithKline, LLC. | $194.08 | 3 | $0 (2022) |
| Incyte Corporation | $192.87 | 7 | $0 (2021) |
| PFIZER INC. | $183.97 | 10 | $0 (2023) |
| Eisai Inc. | $158.16 | 7 | $0 (2024) |
| Merck Sharp & Dohme LLC | $150.89 | 7 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $150.20 | 7 | $0 (2024) |
| Celgene Corporation | $126.18 | 7 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $107.53 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $273.64 | 12 | SOBI, INC ($60.10) |
| 2023 | $558.37 | 27 | Novartis Pharmaceuticals Corporation ($68.25) |
| 2022 | $626.17 | 22 | GlaxoSmithKline, LLC. ($125.00) |
| 2021 | $1,028 | 43 | Janssen Biotech, Inc. ($124.74) |
| 2020 | $465.57 | 22 | PFIZER INC. ($89.43) |
| 2019 | $298.20 | 13 | Incyte Corporation ($116.02) |
| 2018 | $12,992 | 7 | Amgen Inc. ($12,992) |
All Payment Transactions
146 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $22.95 | General |
| Category: Genetically Defined Disease | ||||||
| 12/11/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $23.72 | General |
| Category: Oncology | ||||||
| 12/09/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $33.32 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: Oncology | ||||||
| 10/07/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $21.40 | General |
| Category: Oncology | ||||||
| 09/23/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $26.78 | General |
| Category: IMMUNOLOGY | ||||||
| 09/23/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $18.46 | General |
| Category: Hematology | ||||||
| 06/17/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: Oncology | ||||||
| 04/09/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $20.41 | General |
| Category: Oncology | ||||||
| 01/03/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $22.36 | General |
| Category: Oncology | ||||||
| 10/27/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), PIQRAY | Food and Beverage | In-kind items and services | $23.74 | General |
| Category: Oncology | ||||||
| 10/11/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.95 | General |
| 09/27/2023 | RECORDATI_RARE_DISEASES_INC. | SYLVANT (Drug) | Food and Beverage | In-kind items and services | $21.51 | General |
| Category: ONCOLOGIC AGENT | ||||||
| 09/19/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $22.29 | General |
| Category: Oncology | ||||||
| 09/13/2023 | Seagen Inc. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $31.75 | General |
| Category: Oncology | ||||||
| 07/27/2023 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $26.52 | General |
| Category: Oncology | ||||||
| 07/19/2023 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: Oncology | ||||||
| 07/19/2023 | Emmaus Medical, Inc. | Endari (Drug) | Food and Beverage | In-kind items and services | $9.78 | General |
| Category: Sickle Cell | ||||||
| 06/29/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $23.22 | General |
| Category: Oncology | ||||||
| 06/21/2023 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $21.38 | General |
| Category: Oncology | ||||||
| 05/31/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG, LYNPARZA | Food and Beverage | In-kind items and services | $21.84 | General |
| Category: ONCOLOGY | ||||||
| 05/18/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: ONCOLOGY | ||||||
| 05/11/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug), KISQALI | Food and Beverage | In-kind items and services | $23.76 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 16 | 33 | $8,877 | $3,057 |
| 2021 | 1 | 12 | 29 | $7,551 | $3,284 |
Total Patients
28
Total Services
62
Medicare Billing
$6,341
Procedure Codes
2
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 16 | 33 | $8,877 | $3,057 | 34.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 12 | 29 | $7,551 | $3,284 | 43.5% |
About Dr. Richard Bender, M.D
Dr. Richard Bender, M.D is a Medical Specialty healthcare provider based in Mission Viejo, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255412664.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Bender, M.D has received a total of $16,242 in payments from pharmaceutical and medical device companies, with $273.64 received in 2024. These payments were reported across 146 transactions from 52 companies. The most common payment nature is "Consulting Fee" ($12,850).
As a Medicare-enrolled provider, Bender has provided services to 28 Medicare beneficiaries, totaling 62 services with total Medicare billing of $6,341. Data is available for 2 years (2021–2023), covering 2 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Specialty
- Other Specialties Hematology & Oncology
- Location Mission Viejo, CA
- Active Since 10/18/2006
- Last Updated 07/21/2022
- Taxonomy Code 261QM2500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1255412664
Products in Payments
- Kyprolis (Biological) $12,963
- IMBRUVICA (Drug) $189.12
- Lenvima (Drug) $158.16
- BLENREP (Biological) $153.11
- KEYTRUDA (Biological) $150.89
- Kyprolis (Drug) $98.45
- MONJUVI (Drug) $81.30
- Nplate (Biological) $79.76
- XTANDI (Drug) $79.64
- JAKAFI (Drug) $75.76
- ZEPZELCA (Drug) $72.37
- INLYTA (Drug) $64.84
- SYNAGIS (Drug) $60.10
- Ultomiris (Drug) $59.08
- REBLOZYL (Biological) $54.33
- VENCLEXTA (Drug) $53.65
- ADCETRIS (Biological) $52.12
- ERLEADA (Drug) $50.57
- LONSURF (Drug) $48.45
- LYNPARZA (Drug) $47.11
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.